Rare thrombotic disorder due to a coagulation factors defect

Rare thrombotic disorders due to coagulation factor defects encompass a group of uncommon conditions in which abnormalities in one or more coagulation factors lead to an increased tendency to form blood clots (thrombophilia) rather than the more commonly associated bleeding tendency. These disorders affect the vascular and hematologic systems and can result in venous thromboembolism (deep vein thrombosis, pulmonary embolism) or, less commonly, arterial thrombotic events. The underlying defects may involve gain-of-function mutations or qualitative abnormalities in coagulation factors that shift the hemostatic balance toward a prothrombotic state. Clinical manifestations vary depending on the specific coagulation factor involved but commonly include recurrent deep vein thrombosis, pulmonary embolism, and thrombosis in unusual vascular sites. Some patients may present with pregnancy-related complications such as recurrent miscarriage, preeclampsia, or placental abruption. The age of onset and severity can be highly variable, with some individuals remaining asymptomatic until provoked by additional risk factors such as surgery, immobilization, oral contraceptive use, or pregnancy. Management typically involves anticoagulation therapy, including heparin for acute thrombotic events and long-term oral anticoagulants such as warfarin or direct oral anticoagulants for secondary prevention. The duration and intensity of anticoagulation are guided by the specific defect identified, the severity and recurrence of thrombotic events, and individual patient risk factors. Genetic counseling is recommended for affected families to identify at-risk relatives who may benefit from prophylactic measures during high-risk situations.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Rare thrombotic disorder due to a coagulation factors defect